<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00063986</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000305866</org_study_id>
    <secondary_id>U10CA021115</secondary_id>
    <secondary_id>E2202</secondary_id>
    <nct_id>NCT00063986</nct_id>
  </id_info>
  <brief_title>Esophagectomy in Treating Patients With High-Grade Dysplasia of the Esophagus or Stage I, Stage II, or Stage III Esophageal Cancer</brief_title>
  <official_title>Minimally Invasive Esophagectomy (MIE): A Multicenter Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer and Leukemia Group B</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Laparoscopic-assisted surgery and video-assisted thoracoscopy are less invasive
      types of surgery for esophageal cancer that may have fewer side effects and improve recovery.

      PURPOSE: This phase II trial is studying how well laparoscopic-assisted surgery and
      video-assisted thoracoscopy work in treating patients who are undergoing esophagectomy for
      high-grade dysplasia of the esophagus or stage I, stage II, or stage III esophageal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the feasibility of performing minimally invasive esophagectomy (MIE), in terms
           of 30-day mortality, in patients with high-grade dysplasia of the esophagus or stage
           I-III esophageal cancer.

        -  Determine the complications associated with this procedure in these patients.

        -  Determine the rate at which conversion to open operation is required in patients
           undergoing this procedure.

        -  Determine the length of the operation, duration of intensive care unit stay, and length
           of hospital stay in patients undergoing this procedure.

        -  Determine feasibility and conversion rate of MIE after neoadjuvant therapy.

        -  Assess the effectiveness of lymph node dissection by MIE by recording the total number
           of lymph nodes dissected.

        -  Assess outcomes at follow-up to three years.

      OUTLINE: This is a multicenter study.

      Patients undergo minimally invasive esophagectomy comprising video-assisted thoracoscopy to
      mobilize the thoracic esophagus in combination with laparoscopy to complete the esophagectomy
      and a neck incision to mobilize the cervical esophagus. Mortality at 30 days is assessed.

      Patients are followed every 3 months for 2 years and then every 6 months for 1 year.

      ACTUAL ACCRUAL: A total of 110 patients were accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peri-operative Mortality at 30 Days</measure>
    <time_frame>Assessed at 30 days from surgery</time_frame>
    <description>The primary endpoint is 30-day peri-operative mortality rate. Proportion of patients died within 30 days of surgery will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Conversion to Open Operation</measure>
    <time_frame>Assessed at surgery</time_frame>
    <description>Proportion of patients who required conversion to operation will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Operating Time</measure>
    <time_frame>Assessed at surgery</time_frame>
    <description>The length of the operation (total of thoracic and abdominal components) is recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Intensive Care Stay</measure>
    <time_frame>Assessed after surgery until patients are out of intensive care</time_frame>
    <description>Number of post-operative days in intensive care is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Length of Hospital Stay</measure>
    <time_frame>Assessed after surgery until patients are out of hospital</time_frame>
    <description>The number of days patients stayed in the hospital after surgery is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Lymph Nodes Dissected</measure>
    <time_frame>Assessed at surgery</time_frame>
    <description>The total number of lymph nodes dissected is reported to assess the effectiveness of lymph node dissection by MIE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year Survival Rate</measure>
    <time_frame>Assessed at 3 years</time_frame>
    <description>Patients are followed for survival for 3 years from registration. Overall survival is defined as the time from operation to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day Peri-operative Mortality After Neoadjuvant Therapy</measure>
    <time_frame>Assessed at 30 days after surgery</time_frame>
    <description>Proportion of patients with neoadjuvant therapy died within 30 days of operation is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Conversion to Open Operation After Neoadjuvant Therapy</measure>
    <time_frame>Assessed at surgery</time_frame>
    <description>Proportion of patients with neoadjuvant therapy required conversion to open operation is reported.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Minimally invasive esophagectomy (MIE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Minimally invasive esophagectomy (MIE)</intervention_name>
    <description>Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.</description>
    <arm_group_label>Minimally invasive esophagectomy (MIE)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

        DISEASE CHARACTERISTICS:

          -  High grade dysplasia of the esophagus who would undergo esophagectomy OR esophageal
             cancer at stage T1-T3, N0-N1 who require esophagectomy (patients with M1 disease
             and/or bulky lymph node involvement were excluded).

          -  Pathological confirmation of a diagnosis of cancer or high-grade dysplasia of the
             esophagus by biopsy.

          -  Computerized tomography (CT) scan of chest and abdomen within 6 weeks prior to
             registration

          -  Stomach must be available for conduit

          -  Age of 18 and over

          -  ECOG performance status of 0-2

          -  Creatinine less than 2 mg/dL

          -  Patients with esophageal cancer who would be treated with neoadjuvant chemotherapy
             and/or radiation were eligible. If patients were registered prior to receiving
             neoadjuvant chemotherapy they were allowed up to 5 months to complete therapy and any
             restaging that was necessary before operation was performed.

          -  The patient was considered an appropriate candidate for surgery based on preoperative
             clinical staging and physiological factors prior to registration as documented in the
             surgical plan. Pre-operative staging should include:

               -  Endoscopic ultrasound (EUS)

               -  Positron emission tomography (PET) scan and/or laparoscopic staging (Laparoscopic
                  staging could be performed on the day of resection. Additional evaluation was
                  recommended if the PET scan suggested distant metastatic disease.)

        EXCLUSION CRITERIA:

          -  Cancer extending into the stomach more than 20%

          -  Prior anti-reflux or gastric operations

          -  Prior right thoracotomy

          -  Prior major neck operation other than the removal of superficial skin lesion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James D. Luketich, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31403-3089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University Cancer Research Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hutchinson Area Health Care</name>
      <address>
        <city>Hutchinson</city>
        <state>Minnesota</state>
        <zip>55350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meeker County Memorial Hospital</name>
      <address>
        <city>Lichfield</city>
        <state>Minnesota</state>
        <zip>55355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HealthEast Cancer Care at St. John's Hospital</name>
      <address>
        <city>Maplewood</city>
        <state>Minnesota</state>
        <zip>55109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Piper Cancer Institute at Abbott - Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center - Minneapolis</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masonic Cancer Center at University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HealthEast Cancer Care at St. Joseph's Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Cancer Center at St. Francis Medical Center</name>
      <address>
        <city>Shakopee</city>
        <state>Minnesota</state>
        <zip>55379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regions Hospital Cancer Care Center</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HealthEast Cancer Care at Woodwinds Health Campus</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Missouri Valley Cancer Consortium</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Immanuel Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alegant Health Cancer Center at Bergan Mercy Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creighton University Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131-2197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Rutan Hospital</name>
      <address>
        <city>Bellefontaine</city>
        <state>Ohio</state>
        <zip>43311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adena Regional Medical Center</name>
      <address>
        <city>Chillicothe</city>
        <state>Ohio</state>
        <zip>45601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist Hospital Cancer Care</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214-3998</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Columbus</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grant Medical Center Cancer Care</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Carmel Health - West Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctors Hospital at Ohio Health</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Delaware</city>
        <state>Ohio</state>
        <zip>43015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairfield Medical Center</name>
      <address>
        <city>Lancaster</city>
        <state>Ohio</state>
        <zip>43130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strecker Cancer Center at Marietta Memorial Hospital</name>
      <address>
        <city>Marietta</city>
        <state>Ohio</state>
        <zip>45750</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Licking Memorial Cancer Care Program at Licking Memorial Hospital</name>
      <address>
        <city>Newark</city>
        <state>Ohio</state>
        <zip>43055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Ohio</state>
        <zip>45504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Hospital of Springfield and Clark County</name>
      <address>
        <city>Springfield</city>
        <state>Ohio</state>
        <zip>45505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Carmel St. Ann's Cancer Center</name>
      <address>
        <city>Westerville</city>
        <state>Ohio</state>
        <zip>43081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesis - Good Samaritan Hospital</name>
      <address>
        <city>Zanesville</city>
        <state>Ohio</state>
        <zip>43701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Cancer Institute at Geisinger Health</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Centers</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Group - Scenery Park</name>
      <address>
        <city>State College</city>
        <state>Pennsylvania</state>
        <zip>16801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center</name>
      <address>
        <city>Wilkes-Barre</city>
        <state>Pennsylvania</state>
        <zip>18711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical City Dallas Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2003</study_first_submitted>
  <study_first_submitted_qc>July 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2003</study_first_posted>
  <results_first_submitted>November 29, 2012</results_first_submitted>
  <results_first_submitted_qc>January 4, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 11, 2013</results_first_posted>
  <last_update_submitted>February 7, 2013</last_update_submitted>
  <last_update_submitted_qc>February 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>esophageal cancer</keyword>
  <keyword>minimally invasive esophagectomy (MIE)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was activated on March 3, 2004 and closed on August 15, 2008. A total of 110 patients were accrued for this study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Minimally Invasive Esophagectomy (MIE)</title>
          <description>Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
Only eligible and treated patients are included in the primary analysis.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eligible and Treated</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Intra-operatively ineligible</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Minimally Invasive Esophagectomy (MIE)</title>
          <description>Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
Only eligible and treated patients are included in the primary analysis.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="104"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" lower_limit="36" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peri-operative Mortality at 30 Days</title>
        <description>The primary endpoint is 30-day peri-operative mortality rate. Proportion of patients died within 30 days of surgery will be reported.</description>
        <time_frame>Assessed at 30 days from surgery</time_frame>
        <population>Eligible and treated patients are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Minimally Invasive Esophagectomy (MIE)</title>
            <description>Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
Only eligible and treated patients are included in the primary analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Peri-operative Mortality at 30 Days</title>
          <description>The primary endpoint is 30-day peri-operative mortality rate. Proportion of patients died within 30 days of surgery will be reported.</description>
          <population>Eligible and treated patients are included in this analysis.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.029" lower_limit="0.008" upper_limit="0.073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Conversion to Open Operation</title>
        <description>Proportion of patients who required conversion to operation will be reported.</description>
        <time_frame>Assessed at surgery</time_frame>
        <population>Eligible and treated patients are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Minimally Invasive Esophagectomy (MIE)</title>
            <description>Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
Only eligible and treated patients are included in the primary analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Conversion to Open Operation</title>
          <description>Proportion of patients who required conversion to operation will be reported.</description>
          <population>Eligible and treated patients are included in this analysis.</population>
          <units>Proportion of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.087" lower_limit="0.004" upper_limit="0.158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Operating Time</title>
        <description>The length of the operation (total of thoracic and abdominal components) is recorded.</description>
        <time_frame>Assessed at surgery</time_frame>
        <population>Eligible and treated patients are included in this analysis. Out of 104 eligible and treated patients, 10 patients' length of operation data were unavailable, so the results are based on data from 94 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Minimally Invasive Esophagectomy (MIE)</title>
            <description>Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
Only eligible and treated patients are included in the primary analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Operating Time</title>
          <description>The length of the operation (total of thoracic and abdominal components) is recorded.</description>
          <population>Eligible and treated patients are included in this analysis. Out of 104 eligible and treated patients, 10 patients' length of operation data were unavailable, so the results are based on data from 94 patients.</population>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="330" lower_limit="120" upper_limit="813"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Intensive Care Stay</title>
        <description>Number of post-operative days in intensive care is reported.</description>
        <time_frame>Assessed after surgery until patients are out of intensive care</time_frame>
        <population>Eligible and treated patients are included in this analysis. Out of 104 eligible and treated patients, duration of intensive care stay is missing for 3 patients, so the results are based on data from 101 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Minimally Invasive Esophagectomy (MIE)</title>
            <description>Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
Only eligible and treated patients are included in the primary analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Intensive Care Stay</title>
          <description>Number of post-operative days in intensive care is reported.</description>
          <population>Eligible and treated patients are included in this analysis. Out of 104 eligible and treated patients, duration of intensive care stay is missing for 3 patients, so the results are based on data from 101 patients.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Length of Hospital Stay</title>
        <description>The number of days patients stayed in the hospital after surgery is reported.</description>
        <time_frame>Assessed after surgery until patients are out of hospital</time_frame>
        <population>Eligible and treated patients are included in this analysis. Out of 104 eligible and treated patients, duration of hospital stay is missing for 3 patients, so the results are based on data from 101 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Minimally Invasive Esophagectomy (MIE)</title>
            <description>Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
Only eligible and treated patients are included in the primary analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Length of Hospital Stay</title>
          <description>The number of days patients stayed in the hospital after surgery is reported.</description>
          <population>Eligible and treated patients are included in this analysis. Out of 104 eligible and treated patients, duration of hospital stay is missing for 3 patients, so the results are based on data from 101 patients.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="4" upper_limit="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Lymph Nodes Dissected</title>
        <description>The total number of lymph nodes dissected is reported to assess the effectiveness of lymph node dissection by MIE.</description>
        <time_frame>Assessed at surgery</time_frame>
        <population>Eligible and treated patients are included in this analysis. Out of 104 eligible and treated patients, the number of lymph nodes removed is missing for 1 patient, so the results are based on data from 103 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Minimally Invasive Esophagectomy (MIE)</title>
            <description>Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
Only eligible and treated patients are included in the primary analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Lymph Nodes Dissected</title>
          <description>The total number of lymph nodes dissected is reported to assess the effectiveness of lymph node dissection by MIE.</description>
          <population>Eligible and treated patients are included in this analysis. Out of 104 eligible and treated patients, the number of lymph nodes removed is missing for 1 patient, so the results are based on data from 103 patients.</population>
          <units>Lymph nodes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="2" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>3-year Survival Rate</title>
        <description>Patients are followed for survival for 3 years from registration. Overall survival is defined as the time from operation to death.</description>
        <time_frame>Assessed at 3 years</time_frame>
        <population>Eligible and treated patients are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Minimally Invasive Esophagectomy (MIE)</title>
            <description>Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
Only eligible and treated patients are included in the primary analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>3-year Survival Rate</title>
          <description>Patients are followed for survival for 3 years from registration. Overall survival is defined as the time from operation to death.</description>
          <population>Eligible and treated patients are included in this analysis.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.584" lower_limit="0.477" upper_limit="0.676"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>30-day Peri-operative Mortality After Neoadjuvant Therapy</title>
        <description>Proportion of patients with neoadjuvant therapy died within 30 days of operation is reported.</description>
        <time_frame>Assessed at 30 days after surgery</time_frame>
        <population>35 eligible and treated patients with neoadjuvant therapy are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Minimally Invasive Esophagectomy (MIE)</title>
            <description>Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
Only eligible and treated patients are included in the primary analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>30-day Peri-operative Mortality After Neoadjuvant Therapy</title>
          <description>Proportion of patients with neoadjuvant therapy died within 30 days of operation is reported.</description>
          <population>35 eligible and treated patients with neoadjuvant therapy are included in this analysis.</population>
          <units>Proportion of patients</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.057" lower_limit="0.010" upper_limit="0.169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Conversion to Open Operation After Neoadjuvant Therapy</title>
        <description>Proportion of patients with neoadjuvant therapy required conversion to open operation is reported.</description>
        <time_frame>Assessed at surgery</time_frame>
        <population>35 eligible and treated patients with neoadjuvant therapy are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Minimally Invasive Esophagectomy (MIE)</title>
            <description>Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
Only eligible and treated patients are included in the primary analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Conversion to Open Operation After Neoadjuvant Therapy</title>
          <description>Proportion of patients with neoadjuvant therapy required conversion to open operation is reported.</description>
          <population>35 eligible and treated patients with neoadjuvant therapy are included in this analysis.</population>
          <units>Proportion of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.086" lower_limit="0.018" upper_limit="0.231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Assessed during surgery and for 30 days after the end of treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Minimally Invasive Esophagectomy (MIE)</title>
          <description>Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
Only eligible and treated patients are included in the primary analysis.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Cardiac-ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Cardiac-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Fistula, Colon/cecum/appendix</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Fistula, Esophageal</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Obstruction, small bowel NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Obstruction, stomach</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Stenosis (including anastomotic) esophagus</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>GI-other</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Upper GI, hemorrhage NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Abdomen, pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Esophagus, pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional, other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Death - multiorgan failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Edema limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Edema trunk/genital</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Pleura, pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Pain-other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Colitis, infectious (e.g. C.diff)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Infection w/ Gr0-2 neutropenia, jejunum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Infection w/ Gr0-2 neutropenia, lung</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Infection w/ Gr0-2 neutropenia, mediastinm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Infection w/ Gr0-2 neutropenia, neck NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Infection w/ Gr0-2 neutropenia, pleura</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Infection w/ Gr0-2 neutropenia, upper airway</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Infectionw/ Gr0-2 neutropenia, wound</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Infection w/ unknown ANC foreign body</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Infection w/ unknown ANC lung</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Infection w/ unknown ANC peritoneal cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Infection w/ unknown ANC pleura (empyema)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Infection w/ unknown ANC upper aerodigest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Opportunistic infection lymphopenia&gt;=grade 1</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Infection w/ Gr0-2 neutropenia, blood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound - non-infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Leak (including anastomotic, esophagitis)</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Surgical hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Obstruction, airway-larynx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Prolong intubation post pulm resection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Intra-op injury Spleen</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Intra-op injury Vein inferior vena cava</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Vascular access,Thrombosis/embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>PTT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>ALT increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>AST increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Nonneuropathic generalized weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Chest wall, pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Laryngeal nerve dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Adult Respiratory Distress Syndrome (ARDS)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Chylothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Fistula trachea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Voice changes/dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Chyle or lymph leakage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Voice changes/dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Statistician</name_or_title>
      <organization>ECOG Statistical Office</organization>
      <phone>617-632-3012</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

